Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Phase 4

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Piperacillin-tazobactam combination product

Registration Number: NCT01694069

Lead Sponsor: West Virginia University

Brief Summary: Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas aeruginosa.

Patients with cystic fibrosis require frequent therapy with intravenous (I.V.) antibiotics to treat lung infections thought to be caused by Pseudomonas aeruginosa. One of the antibiotics frequently used to treat this bacteria is piperacillin-tazobactam. Piperacillin-tazobactam is thought to be the most effective when there is a constant level of drug in the body. The standard way to administer piperacillin-tazobactam is to give several grams 4 times each day as a 30 minute infusion. An alternative way to give piperacillin-tazobactam is by a continuous infusion; a continuous infusion will make it more likely that drug will remain at a constant level in the body. The objective of this study is to determine if administering piperacillin-tazobactam as a continuous infusion is more effective at treating people having a pulmonary exacerbation of cystic fibrosis than a standard 30 minute infusion, 4 times a day.

Detailed Description: All patients will receive combination therapy to include piperacillin-tazobactam 400 mg/kg/day (based on piperacillin component, actual body weight) not to exceed 16 grams and tobramycin 12 mg/kg/day extended interval dosing (once daily). Patients randomized to the continuous infusion group will receive a one-time loading dose of 100 mg/kg over 30 minutes followed immediately by initiation of the continuous infusion.

Other antibiotics with activity against Pseudomonas aeruginosa are not allowed. Patients may receive an antibiotic for treatment of Staphylococcus aureus if deemed appropriate.

Other treatments for pulmonary exacerbation of cystic fibrosis will be left up to the control of the treating physician. Patients will receive a total of 14 days of therapy. If deemed appropriate, patients may be discharged to home where they will continue to receive blinded treatment via an infusion pump. Patients will be evaluated after completing their 14 day course of antibiotics (end of therapy).

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 6

Inclusion Criteria

Diagnosis of cystic fibrosis
8 years of age or greater
Chronic or intermittent infection with Pseudomonas aeruginosa as defined by the Leeds Criteria
Pulmonary exacerbation as defined by Fuchs et al.

Exclusion Criteria

Admission for greater than 48 hours prior to enrollment
Isolation of Burkholderia spp. in a respiratory tract culture in the prior 12 months
Current treatment for allergic bronchopulmonary aspergillosis
Pregnant or breast feeding
History of solid organ transplantation
Renal impairment at time of randomization (< 40 mL/min as calculated by the Cockcroft-Gault equation24 ¬for adults or the Schwartz equation45 for those < 18 years of age) or receipt of hemodialysis
Allergy to study medication

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Continuous infusion piperacillin-tazobactam	Piperacillin-tazobactam combination product	Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
Intermittent Infusion piperacillin-tazobactam	Piperacillin-tazobactam combination product	Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day

Primary Outcome Measures

Name	Time	Method
Change in Forced Expiratory Volume at One Second (FEV1)	Baseline, Day 0, and Day 14	FEV1 will be measured upon enrollment (day 0). FEV1 will also be measured at end of therapy (day 14). If FEV1 is available when patient was stable, prior to enrollment, this value will be treated as baseline FEV1. Change in FEV1 will be calculated from baseline (if available) to day 14 and also Day 0 to day 14

Secondary Outcome Measures

Name	Time	Method
Piperacillin Serum Concentrations	Day 3	Serum piperacillin concentration will be measured as follows: * Intermittent infusion arm: prior to dose (trough), 30 minutes (after completion of infusion), and at 4 hours * Continuous infusion arm: collected at the same time as in the intermittent infusion arm
Change in Sputum Density of Pseudomonas Aeruginosa	Day 0, day 3, and day 14	Sputum density of Pseudomonas aeruginosa will be determined at enrollment, day 3, and at end of therapy
Time to Defervescence	Day 0 to day 14	Temperature will be taken multiple times daily according to standard of care. If patients present febrile, time until patient is afebrile and remains afebrile for 24 hours will be recorded.
Time to Normalization of White Blood Cell Count	Day to day 14	White blood cell (WBC) count will be measured once daily. If patient presents with WBC count greater than 11.0 x 10\^3/mL, time until patient has WBC less than 11.0 x 10\^3/mL will be recorded.
Change in Weight	Day 0 and day 14	The change in weight will be documented from enrollment to end of therapy
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score	Day 0 and day 14	The validated CFQ-R will be administered to patients at time of enrollment at end of therapy
Time to Next Pulmonary Exacerbation	Patients will be followed up to 52 weeks from time of enrollment	Patients will be followed for time of next subsequent pulmonary exacerbation for up to 52 weeks after completion of receiving study drug. Next pulmonary exacerbation is defined as requiring admission to a hospital for receipt of I.V. antibiotics because of a diagnosis of pulmonary exacerbation.
Clinical Failure of Treatment	Day 14	Failure of treatment will be defined as patient needing I.V. antibiotics beyond the 14 days allowed in this study. The primary medical team (along with a blinded investigator) treating the patient will determine whether patient requires additional therapy.